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Fibrotic reactions in the airways of the lung or the pulmonary interstitium are a common pathologic outcome after
exposure to a wide variety of toxic agents, including metals, particles or fibers. The survival of mesenchymal cells
(fibroblasts and myofibroblasts) is a key factor in determining whether a fibroproliferative response that occurs after
toxic injury to the lung will ultimately resolve or progress to a pathologic state. Several polypeptide growth factors,
including members of the platelet-derived growth factor (PDGF) family and the epidermal growth factor (EGF)
family, are prosurvival factors that stimulate a replicative and migratory mesenchymal cell phenotype during the
early stages of lung fibrogenesis. This replicative phenotype can progress to a matrix synthetic phenotype in the
presence of transforming growth factor-b1 (TGF-b1). The resolution of a fibrotic response requires growth arrest
and apoptosis of mesenchymal cells, whereas progressive chronic fibrosis has been associated with mesenchymal
cell resistance to apoptosis. Mesenchymal cell survival or apoptosis is further influenced by cytokines secreted dur-
ing Th1 inflammation (e.g., IFN-g) or Th2 inflammation (e.g., IL-13) that modulate the expression of growth factor
activity through the STAT family of transcription factors. Understanding the mechanisms that regulate the survival
or death of mesenchymal cells is central to ultimately developing therapeutic strategies for lung fibrosis.
Background
Fibrosis is a feature of many environmental and occupa-
tional lung diseases where pathological changes occur
either around the conducting airways [1] or within the
pulmonary interstitium of the distal lung parenchyma
[2]. In many instances, the insulting agent causes a sus-
tained and progressive fibroproliferative response that
compromises lung function. In chronic fibrosis, includ-
ing asbestosis [2,3], sarcoidosis [4] and idiopathic pul-
monary fibrosis (IPF), mesenchymal cell survival and
resistance to apoptosis favor the development of pro-
gressive disease that ultimately results in respiratory fail-
ure [5,6]. However, in other instances, the mesenchymal
cell proliferative response to tissue injury by inhaled
agents resolves to varying degrees. For example, asthma
features airway fibrosis, but the lesions are relatively
confined to the distal airways and fibrogenesis generally
does not progress to the lung parenchyma [7,8]. Simi-
larly, the transition metal vanadium pentoxide released
from oil-burning power plants is a cause of occupational
chronic bronchitis resulting in reduced airway function
in workers, yet this disease rarely progresses to chronic
interstitial fibrosis [9]. The precise cellular and molecu-
lar mechanisms that initiate fibrogenesis in the lung can
be quite varied and depend on the insulting agent (e.g.,
metals, fibers, chemotherapeutic drugs, radiation).
Genetic susceptibility also plays a major role in deter-
mining disease progression. Despite the complexities of
gene-environment interactions that serve to initiate lung
fibrogenic reactions, a common denominator that is
central to the progression of fibrosis is airway and inter-
stitial mesenchymal cells that provide the major source
of secreted collagen that defines end stage lung fibrosis.
The term mesenchymal cell is used throughout this
review and includes several phenotypes (fibroblasts,
myofibroblasts, smooth muscle cells and fibrocytes).
T h e r ei sa l s oc o n s i d e r a b l ep l a s t i c i t ya m o n gt h e
mesenchymal cell phenotypes. For example, fibroblasts
are known to differentiate into myofibroblasts in the
presence of transforming growth factor (TGF)-b1. The
most notable mesenchymal phenotype that contributes
the majority of secreted matrix during the fibrogenic
process is the myofibroblast[ 9 ] .A b u n d a n te v i d e n c e
indicates that myofibroblasts provide the major source
of collagen that defines the fibrotic lesion and that
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matrix synthesis by lung mesenchymal cells [2,9].
Because myofibroblasts are the central source of extra-
cellular matrix, the survival of these cells largely deter-
mines overall disease progression. Mesenchymal cell
survival in the lung is a key determinant of whether
fibrosis will progress or resolve. Whether the prolifera-
tive response to injury ultimately resolves through
mesenchymal cell growth arrest and apoptosis or
whether mesenchymal cell survival is sustained to perpe-
tuate chronic and persistent matrix production is the
central topic of this review. The overall premise of resol-
ving versus progressive fibrosis is illustrated in Figure 1.
In both resolving and progressive fibrogenic scenarios,
mesenchymal cell accumulation can result from several
possible mechanisms (recruitment of circulating fibro-
cytes, epithelial-mesenchymal cell transition, or migra-
tion and proliferation of resident lung mesenchymal
cells). However, in resolving fibrosis, the collagen matrix
deposited by mesenchymal cells is degraded by protease
activity such as matrix metalloproteinases and is also
ultimately limited by mesenchymal cell growth arrest
and apoptosis. In contrast, progressive fibrosis is the
result of sustained matrix deposition or lack of matrix
degradation, coupled with mesenchymal cell survival.
Mesenchymal cell survival is likely due to multiple fac-
tors, including enhanced or sustained responsiveness of
these cells to growth factor signals and the resistance of
mesenchymal cells to apoptosis.
Mesenchymal Cell Survival: Enhanced Growth Factor
Responsiveness and Resistance to Apoptosis
The survival of mesenchymal cells is likely due in part
to enhanced responsiveness to growth factors and cyto-
kines that stimulate migration and proliferation or
reduce apoptosis. Enhanced responsiveness to prolifera-
tive and matrix synthetic signals has been reported in
fibroblasts from patients with idiopathic pulmonary
fibrosis (IPF). For example, pulmonary fibroblasts from
IPF patients have spontaneously elevated levels of IL-13
and IL-4 receptor subunits, and it has been suggested
that the abnormal proliferative properties of lung fibro-
blasts from certain lung fibrosis patient groups can be
modulated in a manner that is dependent on the IL-4
and IL-13 receptor expression [10]. Additionally, IPF
fibroblasts stimulated with exogenous TGF-b1, interleu-
kin (IL)-13 or CC-chemokine ligand 2 (CCL2) have sig-
nificantly increased levels of connective tissue growth
factor (CTGF), TGF-b1, and cell-surface receptors for
TGF-b1, IL-13 and platelet-derived growth factor
(PDGF) [11]. This suggests that enhanced responsive-
ness of lung fibroblasts from IPF patients is likely due to
a complex interplay between cytokines, growth factors
and elevated levels of several different cell-surface
receptors.
A major factor that determines mesenchymal cell sur-
vival and the severity of a fibrogenic response is the
resistance of mesenchymal cells to undergo apoptosis
after injury. Myofibroblastsu n d e r g oa p o p t o s i sd u r i n g
Figure 1 Comparison of events that mediate “resolving fibrosis” versus “progressive chronic fibrosis.” Following injury, mesenchymal cell
accumulation and subsequent matrix (e.g., collagen) production occur in both resolving and progressive fibrogenesis. However, mesenchymal
cell apoptosis and degradation of matrix are favored in resolving fibrosis, whereas mesenchymal survival is favored in progressive fibrosis.
Mesenchymal cell survival is likely caused by enhanced growth factor responsiveness and resistance to apoptosis.
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in multiple tissues, including lung, liver and kidney
[12,13]. During excessive scarring, i.e., fibrosis, it has
been suggested that the process of mesenchymal cell
apoptosis cannot take place or is severely reduced [13].
Resistance to apoptosis has been reported in cultured
lung myofibroblasts isolated from patients with IPF, and
resistance to apoptosis could be due to altered IL-6 sig-
naling [14]. Specifically, IL-6 protects against Fas-
induced apoptosis in IPF fibroblasts, and yet it enhances
the apoptotic effect of Fas in normal fibroblasts. These
contrasting effects of IL-6 in normal versus IPF lung
fibroblasts appear to be due to altered cell signaling
involving MAP kinase and STAT-3 transcription factor.
Other factors also likely contribute to the resistance of
mesenchymal cells to apoptosis during fibrogenesis. For
example, patients with IPF have a diminished capacity
to produce prostaglandin (PG)E2,w h i c hr e s u l t si n
increased sensitivity of alveolar epithelial cells to Fas
ligand-induced apoptosis but induces fibroblast resis-
tance to the same stimulus [15].
Epithelial-Mesenchymal Cell Interactions in Lung
Fibrogenesis
In contrast to the resistance of mesenchymal cells in
IPF, epithelial cell apoptosis is widespread [16]. There-
fore, the apoptosis paradox in fibrosis is that epithelial
cells are sensitive to apoptosis during the disease pro-
cess, while mesenchymal cells are resistant to apoptosis.
The airway epithelium serves multiple functions, includ-
ing protection against inhaled toxicants, clearance of
particles and fibers from the lung via the mucociliary
apparatus, and repair processes mediated by soluble
cytokines, growth factors, lipid mediators and protei-
nases [17]. Dramatic changes to the architecture of the
airway walls occur as a result of epithelial injury in
patients with asthma, cystic fibrosis and chronic
obstructive pulmonary disease (COPD) [18]. Likewise,
injury to type I epithelial cells of the alveolar region
plays a critical role toward initiating interstitial lung
fibrosis [5]. Because of the many protective and homeo-
static functions of the airway epithelium, damage to the
epithelial lining and subsequent apoptosis plays a major
role in fibrogenesis if adequate repair does not occur
following injury. As such, there is a constant struggle
within the airway microenvironment to repair sites of
injured epithelium while limiting mesenchymal cell
activity and matrix deposition. In general terms, the pro-
gression of lung fibrosis is favored by the combination
of epithelial cell death and mesenchymal cell survival.
The recovery of an intact epithelium following lung
injury is critical for restoration of lung homeostasis [19].
Failure to repair the epithelial barrier promotes
mesenchymal cell survival and matrix production. Some
growth factors, including members of the epidermal
growth factor (EGF) family, discussed in more detail
below, can play dual roles in repairing injured epithe-
lium and yet also stimulate mesenchymal cell survival.
Proper communication between epithelial cells lining
the airways and the underlying mesenchymal cells is cri-
tical for maintaining normal tissue function and home-
ostasis in the lung. The structure that comprises the
airway epithelium and the underlying mesenchymal tis-
sue and extracellular matrix has been referred to as the
epithelial-mesenchymal cell trophic unit (EMTU), and
structure-function relationships between EMTU ele-
ments has been most extensively applied to evolving
theories on the pathogenesis of asthma [20]. However,
these EMTU structure-function relationships also apply
to other chronic airway diseases such as COPD as well
as interstitial lung diseases of the alveolar region that
include asbestosis, silicosis and IPF.
Rodent models of fibrotic airway and interstitial lung
diseases have been extremely valuable in elucidating
mechanisms of epithelial-mesenchymal cell interaction
and formulating new ideas related to the importance of
the EMTU in lung fibrosis. For example, vanadium pent-
oxide (V2O5)-induced airway injury is a useful rodent
model to study the relationship between airway epithelial
cell activation and differentiation in the context of
mesenchymal cell survival and fibrosis [21]. Lung injury
c a u s e db yas i n g l ea d m i n i s t r a t i o no fV 2O5 is followed by
a multistep fibrogenic process that consists of (1) epithe-
lial cell activation and differentiation, macrophage accu-
mulation and mesenchymal proliferation; and (2)
collagen production by the mesenchymal cells followed
by apoptosis, which serves to resolve the fibrogenic
response. Similar pathologic events are seen in a murine
model of allergic airway disease caused by sequential
exposure to ovalbumin and nanoparticles [22]. The com-
mon pathological features of airway remodeling caused
by a partially resolving fibrogenic response to oxidative
stress from metals, fibers, particles or nanoparticles are
illustrated in Figure 2. In both of these scenarios, the air-
way epithelium is activated to differentiate from a
ciliated, serous cell phenotype to a hypersecretory epithe-
lium. Epithelial differentiation is accompanied by
mesenchymal cell accumulation and proliferation around
airways. Mesenchymal cells become activated to secrete a
collagen matrix. However, the fibrogenic process is par-
tially resolved in that the majority of myofibroblasts dis-
appear, presumably through apoptotic pathways.
Tissue homeostasis within the EMTU is tightly regu-
lated by a multiplicity of secreted factors produced by
the epithelium, infiltrating inflammatory cells and the
underlying mesenchymal cells. It is also likely that phy-
sical contact between epithelial cells and mesenchymal
cells is important to maintaining normal airway
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mesenchymal cells have been demonstrated to contact
the epithelial basement membrane [23]. Physical contact
between epithelium and mesenchymal cells is likely dis-
rupted during fibrogenesis by deposited extracellular
matrix. The epithelium secretes growth factors (e.g.,
HB-EGF, TGF-a) that serve to repair the epithelial bar-
rier after injury, and yet these same factors promote sur-
vival, replication, and migration of subepithelial
mesenchymal cells [8]. These secreted growth factors
are important to tissue homeostasis and repair but also
play important roles in fibrogenesis when their expres-
sion or signaling is dysregulated.
The PDGF Family: Prosurvival Factors for
Mesenchymal Cells
The mesenchymal cell response to injury by fibrogenic
agents is mediated by a variety of secreted factors (cyto-
kines, chemokines, and growth factors) that activate
intracellular signaling pathways through their cognate
receptors. The cell types that serve as potential sources
of these soluble mediators to influence mesenchymal
Figure 2 Mesenchymal cell survival in the progression of airway fibrosis following injury by environmental factors. Airway injury occurs
after the inhalation of a variety of inhaled metals, fibers, particles or nanoparticles. After initial injury by particle insult, the airway epithelium
produces chemokines that attract macrophages. Both macrophages and the epithelium produce cytokines, chemokines and growth factors that
stimulate mesenchymal cell (fibroblast and myofibroblast) accumulation within days. Airway smooth muscle also undergoes hyperplasia and
hypertrophy after particle injury. Mesenchymal cells undergo growth arrest and apoptosis, but leave deposited extracellular matrix (e.g., collagen)
that defines the airway fibrotic lesion.
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nuclear phagocytes (e.g., macrophages), lymphocytes,
and mesenchymal cells themselves. As illustrated in Fig-
ure 3, a variety of toxic metals and metal-containing
particles and fibers activate airway epithelial cells and
macrophages to secrete cytokines (e.g., IL-1b,T N F - a)
and growth factors (e.g., HB-EGF, PDGF) that stimulate
myofibroblast replication and chemotaxis (directed
migration). These cells also produce TGF-b1 that stimu-
lates or activates the transition of fibroblasts from a
“replicative and migratory” phenotype to a “matrix syn-
thetic” myofibroblast phenotype [24].
Platelet-derived growth factor (PDGF) is a key factor
in the survival and differentiation of mesenchymal cells
during lung development, and PDGFs are also important
for tissue repair following injury in adult tissues. How-
ever, overexpression of PDGF or its receptors is thought
to play a pivotal role in the progression of fibrotic dis-
eases [25]. The cellular responses to PDGF signaling
include proliferation, migration, control of differentia-
tion, and survival [25,26]. There are four PDGF genes,
designated A-D, that encode four homodimeric protein
isoforms (PDGF-AA, -BB, -CC, and -DD) and one het-
erodimeric isoform (PDGF-AB). There are also two
PDGF receptors, PDGF-Ra and PDGF-Rb, that dimerize
upon ligand binding, forming three isoforms (PDGF-
Raa,- R ab,a n d- R bb). PDGF-AA and PDGF-CC bind
exclusively to PDGF-Ra, whereas PDGF-BB, -AB, and
-DD isoforms bind both PDGF-Ra and PDGF-Rb [27].
PDGF activates multiple intracellular signaling mole-
cules that play important roles in mesenchymal cell sur-
vival, including MAP kinases and the STAT family
members STAT-1 and STAT-3.
Abundant evidence indicates that PDGF and its recep-
tors are important in mediating the pathogenesis of air-
way and interstitial lung fibrosis [25]. First, PDGF
ligands are elevated in patients with idiopathic pulmon-
ary fibrosis, and immunohistochemical studies have
shown that increased expression of PDGFs occurs at
sites of fibroproliferative lesions [28]. Second, the
expression of PDGF and its receptors are increased in
lung tissue during the mesenchymal cell proliferative
phase of pulmonary fibrosis in rodent models where
injury is induced by agents such as bleomycin [29,30],
asbestos [31,32], metals [33] or nanoparticles [34,35].
Third, PDGFs are potent mitogens and chemoattrac-
tants for mesenchymal cells in lung and other organ sys-
tems [25], and PDGF receptor activation is essential for
mesenchymal cell migration in wound healing [36].
Fourth, PDGF is produced by lung macrophages, epithe-
lial cells and mesenchymal cells in vitro following stimu-
lation with particles or fibers [37,38]. As illustrated in
Figure 3, PDGF ligands secreted by epithelial cells and
macrophages contribute to the replicative and migratory
myofibroblast phenotype. Finally, transgenic mouse stu-
dies demonstrate critical roles for PDGF in mesenchy-
mal cell survival in the lung. Knockout mutants for
PDGF-B, PDGF-Rb,a n dP D G F - R a are lethal due to
defects in embryonic development [39]. Knockout of the
PDGF-A gene in mice causes a lethal emphysema-like
phenotype due to failure of myofibroblast development
and subsequent formation of alveolar septum [40,41]. A
similar phenotype is seen in genetically partially rescued
PDGF-Ra-null mutants [42]. The targeted overexpres-
sion of PDGF ligands in the lungs of transgenic mice
produces a lethal phenotype associated with hyperplasia
of mesenchymal cells [43-46]. Collectively, these trans-
genic studies indicate that PDGF and its receptors are
critical to lung mesenchymal cell survival during pul-
monary fibrogenesis.
PDGF and its receptors are potentially important ther-
apeutic targets in pulmonary fibrosis. Because PDGF is a
key mitogen and chemoattractant for mesenchymal cells,
targeting PDGF or its receptors could be effective in
limiting the replication of these cells and reducing col-
lagen deposition and matrix formation. Inhibition of
PDGF activity with kinase inhibitors has been demon-
strated to significantly reduce lung fibrosis in animal
models [47-50]. Imatinib mesylate (Gleevec), an inhibi-
tor of PDGFR tyrosine kinase and c-Abl, has been evalu-
ated in a clinical trial for the treatment of IPF [51].
However, a recent study showed no significant beneficial
effect of imatinib on IPF. Agents that downregulate
PDGFR expression at the cell surface of mesenchymal
cells could also be of potential therapeutic value. For
example, PGE2, an arachidonic acid metabolite gener-
ated by the cyclooxygenase-2 (COX-2) enzyme, is pro-
tective in lung fibrosis partly because it downregulates
the PDGF-Ra and suppresses fibroblast growth [52].
Unlike TGF-b1, which also downregulates PDGF-Ra,
PGE2 does not stimulate collagen secretion by fibro-
blasts. Reduced PGE2 results in enhanced epithelial cell
apoptosis and yet increases mesenchymal cell resistance
to apoptosis [15]. Although COX-2 is a therapeutic tar-
get for arthritis, there is considerable evidence that
COX-2 serves a protective role in pulmonary fibrosis.
For example, COX-2-deficient mice are susceptible to
pulmonary fibrosis induced by V2O5 or bleomycin and
produce lesser quantities of PGE2 [53,54]. In addition,
COX-2 deficiency in mice results in a loss of the anti-
proliferative response to TGF-b1 [55]. This is further
evidence that suggests COX-2 is protective through lim-
iting mesenchymal cell survival.
The EGF Family: The Duality of Protecting Epithelial
and Mesenchymal Cells
The EGF family of ligands mediate numerous cellular
activities, including proliferation [56], adhesion [57],
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influence mesenchymal cell survival and phenotype. Particle-stimulated airway epithelial cells and alveolar macrophages produce soluble
cytokines and growth factors that stimulate the replication and migration of myofibroblasts. EGFR ligands (HB-EGF and TGF-a) are produced by
airway epithelial cells that stimulate epithelial repair and differentiation in an autocrine manner, but also stimulate myofibroblast replication.
PDGF-AA and PDGF-BB produced by epithelial cells and macrophages, respectively, drive replication and chemotactic migration of
myofibroblasts. IL-1b enhances the activity of PDGF-AA and PDGF-BB by upregulating PDGF receptor-a (PDGFRa) expression. Macrophages are
also an abundant source of TNF-a, which stimulates TGF-b1 production by macrophages in an autocrine manner. TGF-b1 stimulates
myofibroblast collagen production and growth arrest, which defines a “matrix synthetic phenotype.” The myofibroblast phenotype is further
defined by a Th1 or Th2 microenvironment. In the presence of Th1 lymphocytes, IFN-g produced by Th1 cells or IFN-b produced by
myofibroblasts stimulates growth arrest and cell death of myofibroblasts and leads to the resolution of a fibrogenic response and tissue repair. In
the presence of Th2 lymphocytes, IL-13 produced by Th2 cells activates myofibroblasts to produce PDGF-AA and TGF-b1 in an autocrine
manner, which drives myofibroblast survival, replication and matrix production to enhance and sustain a fibrogenic response.
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EGF ligands bind to a complex system of cell surface
receptors, termed the ErbB system, composed of four
membrane-associated proteins, ErbB1 (also known as
EGFR), ErbB2 (an orphan receptor), ErbB3 and ErbB4.
Like PDGF receptors, each of the ErbB receptors con-
sists of an extracellular ligand-binding domain, a short
membrane-spanning region and a cytoplasmic region
possessing tyrosine kinase enzymatic activity. EGF
ligands include EGF, transforming growth factor-a
(TGF-a), heparin-binding EGF-like growth factor
(HB-EGF), amphiregulin (AR), neuregulin (NRG), beta-
cellulin, epiregulin and epigen. The EGF ligands bind
differentially to the ErbBs and initiate homodimeric or
heterodimeric receptor dimerization to cause tyrosine
phosphorylation of intracellular receptor residues and
downstream cell signaling through mitogen-activated
protein (MAP) kinases, phosphatidylinositol 3-kinase
(PI3K), and transcription factors including STAT-3
[60,61].
The EGFR ligands are important to epithelial repair
following injury, and as illustrated in Figure 3, certain
EGFR ligands (TGF-a, HB-EGF) also play important
roles in the pathogenesis of pulmonary fibrosis by pro-
moting mesenchymal cell survival and proliferation [8].
Therefore, their role has been described as both protec-
tive against acute lung injury or profibrogenic, depend-
ing on the context of lung injury or the inciting agent.
For example, the administration of recombinant amphir-
egulin attenuates bleomycin-induced pulmonary fibrosis
in mice, suggesting a protective role for this EGFR
ligand [62]. TGF-a p l a y sap r o t e c t i v er o l ea g a i n s t
nickel-induced lung injury by increasing levels of surfac-
tant proteins [63]. However, the targeted overexpression
of TGF-a to distal airway epithelium or conditional
expression of TGF-a in mouse lung results in pulmon-
ary fibrosis [64,65]. Alternatively, TGF-a deficiency pro-
tects mice from bleomycin-induced fibrosis [66].
Therefore, it is likely that TGF-a exerts its beneficial
effects through promoting epithelial repair and increased
surfactant production, whereas its profibrogenic activity
is most likely linked to its activity as a potent mitogen
for mesenchymal cells. In addition, it appears that short-
term TGF-a expression stimulates epithelial cell growth
and repair during acute lung injury, whereas long term
TGF-a expression leads to excessive mesenchymal cell
growth and stimulation of matrix deposition and fibro-
sis. HB-EGF is also a potentially important mitogen for
mesenchymal cells. Human airway epithelial cells and
human lung fibroblasts both produce HB-EGF in
response to vanadium-induced oxidative stress [67,68].
These studies using human cells indicated that paracrine
signaling between the airway epithelium and underlying
mesenchymal cells as well as autocrine production of
HB-EGF by mesenchymal cells could be important to
airway fibrogenesis caused by metal injury. Treatment
with the EGFR kinase inhibitor AG1478 prior to the
instillation of vanadium oxide ameliorates pulmonary
fibrosis [47]. Also, AG1478 attenuates upregulation of
p r o c o l l a g e ne x p r e s s i o ni nt racheal explants from rats
exposed to cigarette smoke [69]. Therefore, several lines
of evidence indicate that signaling through EGFR is
important to both mesenchymal cell proliferation and
matrix production during fibrogenesis. However, unlike
PDGF family members, which are primarily mesenchy-
mal cell survival factors, EGF ligands are also important
survival factors for the lung epithelium and therefore
appear to function in both repair following injury as
well as disease progression.
Th1 versus Th2 Inflammation in Mesenchymal Cell
Survival and Lung Fibrosis
Although polypeptide growth factors such as PDGF and
EGF ligands are important for maintaining mesenchymal
cell survival and proliferation, the survival of these cells
is also determined in large part by the type of inflamma-
tory microenvironment. Within these microenviron-
ments, mesenchymal cells are bathed in a variety of
cytokines, chemokines and lipid mediators that influence
cell survival. Some of these factors that modulate
mesenchymal cell survival and phenotype are illustrated
in Figure 3. Inflammatory reactions are characterized by
the infiltration of mononuclear cells including macro-
phages, lymphocytes, neutrophils and eosinophils.
Although inflammation typically precedes fibrosis, evi-
dence from experimental animal models of fibrosis and
clinical studies where anti-inflammatory drugs have little
effect on lung fibrosis suggest that inflammation may
not be required for fibrogenesis [6]. However, the idea
that inflammation and fibrosis may be distinct processes
is likely an oversimplification, as it is apparent that
inflammatory cytokines and chemokines have potent
modulatory effects on growth factor activity. For exam-
ple, during asthma, infiltrating Th2 lymphocytes pro-
duce interleukin-13 (IL-13), a key cytokine that
mediates multiple phenotypes of airway remodeling,
including mucus cell metaplasia, eosinophilia, airway
smooth muscle thickening and airway fibrogenesis [8].
IL-13 has also been proposed to play a role in some ani-
mal models of interstitial lung fibrosis models, including
bleomycin and FITC [70]. Transgenic mice that overex-
press IL-13 develop tissue fibrosis through production
and activation of TGF-b1 [71]. Studies using a bleomy-
cin-induced pulmonary fibrosis demonstrated that IL-13
signaling through the IL-13a2 receptor is involved in
induction of TGF-b1 production and fibrosis [72]. The
proliferation of lung myofibroblasts in response to IL-13
is mediated through the autocrine release of PDGF-AA
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generated during a Th2 inflammatory response is
important in airway and interstitial fibrosis due in part
to its ability to increase PDGF and TGF-b1, which in
turn influence mesenchymal cell survival and collagen
deposition.
Although IL-13 appears to be central to the patho-
genesis of airway fibrosis in asthma and in some ani-
mal models of interstitial fibrosis, other models of lung
fibrosis are not dependent on Th2 inflammation and
IL-13. For example, V2O5-induced lung fibrosis in
mice features Th1 inflammation and elevated levels of
interferon-g (IFN-g) and IFN-inducible cytokines along
with elevated levels of profibrogenic growth factors
(PDGF-CC, CTGF, TGF-b1) and collagen with no
apparent increases in IL-13 [74]. IFN-g is a potent Th1
lymphokine that inhibits mesenchymal cell growth and
stimulates apoptosis [75]. As illustrated in Figure 3,
IFNs play an important role in mediating myofibro-
blast growth arrest and apoptosis that favors the reso-
l u t i o no faf i b r o g e n i cr e s p o n s e .B e c a u s eo ft h ep o t e n t
growth arrest activity toward normal mesenchymal
cells, IFN-g was investigated and tested in clinical trials
as a potential antifibrotic therapeutic agent. Although
initial preliminary studies indicated antifibrotic poten-
tial [76], a blinded follow-up study showed no consis-
tent beneficial effects of IFN-g on the survival of IPF
patients [77]. This could be due to the refractive nat-
ure of a well-established collagen matrix that com-
prises end-stage fibrotic lesions or other properties of
IFN-g that influence the progression of fibrosis. For
example, although IFN-g is antimitogenic toward lung
fibroblasts, it also enhances particle-induced PDGF
production by alveolar macrophages [78] and enhances
the proliferative activity of PDGF and EGF for lung
fibroblasts isolated from mice deficient in the STAT-1
transcription factor [79].
In addition to IFN-g, the classic proinflammatory cyto-
kines IL-1b and TNF-a are increased in V2O5-induced
lung fibrosis in mice and rats [53]. A variety of fibro-
genic agents, including particles and fibers, increase the
secretion of IL-1b by alveolar macrophages [80]. IL-1b
has been shown to increase the production of PDGF by
mesenchymal cells [81] and is also a potent inducer of
the PDGFRa on rat lung myofibroblasts [82]. IL-1b
overexpression in mice causes pulmonary fibrosis [83],
and more recent work shows that IL-1b enhances bleo-
mycin-induced fibrosis by upregulating IL-17A [84].
Although IL-13 was also upregulated in this study using
the bleomycin model, its expression was at a relatively
late stage and occurred after collagen deposition. Never-
theless, it is likely that IL-13 contributes to chronic
interstitial pulmonary fibrosis by promoting mesenchy-
mal cell survival.
Overlapping Th1 and Th2 inflammatory responses can
occur when individuals with allergic asthma are exposed
to agents that normally elicit only a Th1 inflammatory
response. In this case, the mixture of IL-13 and IFN-g
are largely antagonistic, where IL-13 promotes mesench-
ymal cell survival and IFN-g inhibits mesenchymal cell
growth and stimulates apoptosis. However, IL-13 and
IL-b can act coordinately on rat lung myofibroblasts to
enhance their proliferation. For example, the effect of
IL-13-induced PDGF-AA production by rat lung myofi-
broblasts is further amplified by IL-1b, which upregu-
lates the PDGF-Ra [85]. Carbon nanotubes or V2O5
elicit a Th1 inflammatory response in the lungs of mice
or rats, characterized by increased levels of IFNs and
IFN-inducible chemokines, as well as PDGF [23,74]. In
mice that develop an allergic airway Th2 inflammatory
response induced by ovalbumin challenge, carbon nano-
tube exposure synergistically increases airway fibrosis
[22]. In this case, the combined effects of Th1 and Th2
inflammation resulted in an enhanced fibrogenic
response.
STAT Transcription Factors as Mediators of
Mesenchymal Survival
Many of the cytokines and growth factors mentioned
above that regulate mesenchymal cell survival or
mesenchymal cell growth arrest and apoptosis act via a
family of transcription factors termed the signal transdu-
cers and activators of transcription (STATs) [86,87].
Some of the possible STAT-dependent signaling out-
comes that occur in mesenchymal cells that influence
the progression or resolution of lung fibrosis are illu-
strated in Figure 4. STATs were originally identified
because of their ability to transduce signals from a cellu-
lar receptor into the nucleus and thereby modulate the
transcription of specific genes. Upon ligand binding,
receptor kinases activate latent cytoplasmic STATs
through tyrosine phosphorylation [88]. The STAT pro-
teins then homo-or heterodimerize and translocate to
the nucleus, where they bind to DNA and modulate
gene expression. STAT family members bind with vary-
ing affinities to a canonical palindromic sequence
(TTCN2-4GAA) in the promoters of their target genes
[89]. STATs play prominent roles in both pro-and anti-
inflammatory processes, including cell proliferation,
apoptosis and differentiation. In the context of this
review, STATs are pivotal in mediating both mesenchy-
mal cell survival and mesenchymal cell death.
Interferons (IFNs) are important in resolving fibrogen-
esis and activate STAT-1 signaling pathways for
mesenchymal cell growth arrest and apoptosis. Tran-
scriptionally active STAT-1 is required for the antipro-
liferative and proapoptotic effects of IFNs on
mesenchymal cells [87]. Therefore, STAT-1 is central to
Bonner Fibrogenesis & Tissue Repair 2010, 3:15
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Page 8 of 14Figure 4 STAT transcription factor signaling outcomes in mesenchymal cells that contribute to pulmonary fibrogenesis.M u l t i p l e
signals, either endogenous factors (cytokines and growth factors) or environmental factors (metals, particles, nanoparticles), activate STAT
signaling that leads to outcomes involved in fibrogenesis and tissue repair. IL-13 is increased by allergens or certain metals and particles to
activate STAT-6, which in turn results in Th2 inflammatory responses that include the production of profibrogenic growth factors, PDGF-AA and
TGF-b1. These growth factors are also increased by metals, particles and nanoparticles. PDGF-AA and HB-EGF stimulate STAT-3 to turn on a
mesenchymal cell “survival program.” Metals and particles also increase the production of reactive oxygen species (ROS) through NADPH oxidase
activity or increase the production of interferons (IFNs). ROS or IFNs stimulate STAT-1 to promote growth arrest and apoptosis of mesenchymal
cells. Therefore, the proapoptotic action of STAT-1 opposes the prosurvival and antiapoptotic actions of STAT-3 and STAT-6 for mesenchymal
cells.
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Page 9 of 14mediating the effects of IFNs in the lung by regulating
mesenchymal cell growth arrest and apoptosis, which
favors the resolution of a fibroproliferative response.
STAT-1
-/- mice show no overt developmental abnormal-
ities but display a complete lack of responsiveness to
either IFN-g or IFN-a and are susceptible to infection by
microbial pathogens [90,91]. However, STAT-1
-/- mice
develop more severe pulmonary fibrosis after lung injury
with bleomycin [79]. This study indicated that STAT-1
-/-
mice are more susceptible than wild-type mice to bleo-
mycin-induced lung fibrosis owing to (1) enhanced fibro-
blast proliferation in response to growth factors (EGF
and PDGF), (2) stimulation of fibroblast growth by a
STAT-1-independent IFN-g signaling pathway, and (3)
increased activation of STAT-3. PDGF-BB or EGF have
significantly greater proliferative effects on fibroblasts
isolated from the lungs of STAT-1
-/- mice compared to
wild-type (STAT-1
+/+) mice [79]. Moreover, STAT-3
activation in response to PDGF or EGF, a prosurvival sig-
naling event for mesenchymal cells, is significantly
greater in STAT-1
-/- mouse lung fibroblasts compared to
STAT-1
+/+ fibroblasts. These findings indicate that
STAT-1
-/- mice are more susceptible to bleomycin-
induced lung fibrosis than STAT-1
+/+ mice owing to
enhanced fibroblast proliferation in response to growth
factors (PDGF and EGF) and increased activation of
STAT-3. In addition, IFN-g has a proliferative effect on
fibroblasts isolated from the lungs of STAT-1
-/- mice,
whereas IFN-g is growth inhibitory to fibroblasts isolated
f r o mt h el u n g so fw i l d - t y p eS T A T - 1
+/+ mice [79]. These
findings indicate that IFNs exert dual antimitogenic
effects via STAT-1 and promitogenic effects via STAT-1-
independent signaling pathways. This dual action may
explain why IFN-g has not proven to be an effective ther-
apy in patients with IPF [77]. In addition to studies show-
ing that deletion of STAT-1 potentiates bleomycin-
induced lung fibrosis in mice, other work demonstrated
that aerosolized STAT-1 antisense oligodeoxynucleotides
decreased the concentrations of TGF-b, PDGF and TNF-
a in bronchioalveolar lavage fluid (BALF) in bleomycin-
induced rat pulmonary injury and ameliorated bleomy-
cin-induced pulmonary fibrosis [92]. Finally, more trans-
lational work with human lung fibroblasts shows that
IFN-g inhibits TGF-b1-induced signaling and collagen
production via STAT-1 [93]. All of these studies clearly
indicate that STAT-1 plays a protective role in limiting
mesenchymal cell survival and resolving lung fibrosis.
Furthermore, the development of novel agonists that
activate STAT-1 may prove beneficial for managing or
treating pulmonary fibrosis.
While STAT-1 is principally activated by IFNs
through their cognate cell-surface receptors on
mesenchymal cells, reactive oxygen species (ROS) are
also capable of activating STAT-1 [94]. A variety of
environmental factors (e.g., metals, air pollution particu-
late matter, nanoparticles, cigarette smoke, ozone) gen-
erate ROS that activate intracellular signaling cascades.
For example, STAT-1 activated by the transition metal
V2O5 is blocked by anti-oxidants N-acetyl-L-cysteine or
catalase [95]. More recent findings showed that STAT-1
activation in human lung fibroblasts by V2O5 required
NADPH oxidase-generated ROS and autocrine produc-
tion of IFN-b [96]. This resulted in antifibrogenic sig-
nals, including growth inhibition but also the increased
expression of the IFN-inducible chemokine CXCL10.
CXCL10 is a pleiotropic molecule that elicits potent bio-
logical effects, including chemotaxis of activated T and
NK cells, modulation of adhesion molecule expression,
and inhibition of angiogenesis [97,98]. CXCL10 reduces
bleomycin-induced pulmonary fibrosis in mice via inhi-
bition of angiogenesis [99]. Deletion of CXCR3, the
receptor for CXCL10, increases bleomycin-induced
fibroproliferation and mortality in mice [100]. Therefore,
our findings support the hypothesis that STAT-1, IFNs
and CXCL10 are protective factors in the lung that limit
the severity of a fibrogenic response and promote the
resolution of fibrosis. These events act in opposition to
and occur after the profibrogenic actions of V2O5 in
mice and rats that results from increased expression and
activation of profibrogenic growth factors such as
PDGF, TGF-b1, and CTGF.
Whereas STAT-1 plays a key role in promoting apop-
tosis in a variety of cell types and has antiproliferative
effects, STAT-3 acts in opposition to STAT-1 and has
an antiapoptotic effect and promotes mesenchymal cell
proliferation [101,102]. In contrast to deletion of STAT-
1 or STAT-6, STAT-3 deletion in mice is lethal and
therefore little is known about the role of STAT-3 in
lung fibrosis. STAT-3 is generally thought to promote
the survival of lung mesenchymal cells in response to
growth factor stimulation [101]. Fibroblasts isolated
from normal human lung do not proliferate in response
to IL-6 due to prolonged STAT-3 signaling, whereas
fibroblasts from IPF patients proliferate in response to
IL-6 [103]. This mechanism involved a shift in signaling
dependency from STAT-3 in normal human fibroblasts
to ERK in IPF fibroblasts. While STAT-3 deletion in
mice is lethal, the selective deletion of STAT-3 gene in
respiratory epithelial cells by conditional expression of
Cre-recombinase under control of the surfactant protein
C gene promoter did not alter prenatal lung morpho-
genesis or postnatal lung function [104]. However, expo-
sure of adult STAT-3-deleted mice to hyperoxia caused
a more rapidly progressive lung injury associated with
alveolar capillary leak and acute respiratory distress, sug-
gesting that STAT-3 plays a critical role in maintenance
of surfactant homeostasis and lung function during oxy-
gen injury in adult lung tissue.
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and IL-4, but not by polypeptide growth factors such as
PDGF and EGF that mediate mesenchymal cell survival.
However, as mentioned above, these growth factor
families are induced by IL-13 and this signaling is
accomplished through STAT-6 [8]. STAT-6 mediates
many of the biological effects of IL-13 during asthma
pathogenesis and fibrosis. All of these characteristics of
airway remodeling in asthma (eosinophilia, mucous cell
metaplasia, airway fibrogenesis) are absent in a model of
allergic asthma in STAT-6-deficient mice [105]. A pri-
mary role for IL-13 in asthma and Th2-mediated fibro-
genic reactions is the production of TGF-b1v i aa
STAT-6-dependent mechanism [71,72]. STAT-6 also
mediates IL-13-induced production of PDGF-AA in
rodent and human lung fibroblasts [73]. Therefore,
STAT-6 plays a central role in orchestrating the expres-
sion of profibrogenic growth factors during allergic lung
diseases and fibrosis. While STAT-6 is the primary sig-
naling intermediate for the biological effects of IL-13,
STAT-1 is also activated by IL-13 in a variety of lung
cell types [106]. However, STAT-1 antagonizes IL-13-
induced signaling in lung cell types [107,108]. Therefore,
a common theme is that STAT-1, activated by IFNs,
antagonizes STAT-6 and STAT-3 to exert opposing bio-
logical effects mediated by IL-13 or growth factors,
respectively.
Conclusions
Lung fibrosis encompasses a wide spectrum of diseases
and disorders that are initiated and perpetuated by a
complex interplay of genes and environment. Despite
the diversity of causes for fibrosis and the multiple
mechanisms that initiate the disease process, a common
denominator that is pivotal to disease progression is sur-
vival of mesenchymal cells. Nevertheless, current treat-
ment strategies have not been effective in preventing or
managing pulmonary fibrosis. Apoptosis of fibroblasts is
required for successful wound healing and termination
of collagen deposition [70], and resistance to apoptosis
has been observed in fibroblasts from IPF patients [103].
Therefore, promoting mesenchymal cell apoptotic path-
ways at the appropriate time after lung tissue repair may
help slow the progression of fibrosis. Targeted therapy
aimed at growth factors (e.g., PDGF or TGF-b1) and
their receptors to limit mesenchymal cell survival and
collagen deposition seems a logical path for the treat-
ment of fibrosis, given the important roles that these
growth factors play in mesenchymal cell survival and
collagen production. However, while growth factor tyro-
sine kinase inhibitors showed promising results in
attenuating lung fibrosis in experimental animal models,
recent studies with kinase inhibitors (e.g., imatinib
mesylate or Gleevec) have shown no effect on the
survival or lung function of patients with IPF [109].
Likewise, clinical trials with IFN-g, which also showed
promising results in animal models of pulmonary fibro-
sis, have failed to show any significant beneficial effect
in IPF patients [77]. As discussed in more detail above,
IFN-g is clearly growth inhibitory to mesenchymal cells
through STAT-1 signaling, but there is also evidence
that indicates IFN-g can promote mesenchymal cell sur-
vival through STAT-1-independent signaling [79]. It has
been suggested that animal models of pulmonary fibro-
sis (e.g., bleomycin) do not adequately model IPF. How-
ever, fibrotic reactions in IPF patients undergoing
treatment with IFN-g or imatinib are relatively end stage
after much tissue scarring has occurred, and interfering
with mesenchymal cell survival at this point may simply
come at a stage that is too late to be effective. Imatinib
therapy might be effective in the early stages of fibro-
genesis as in patients undergoing lung transplant who
suffer a high incidence of bronchiolitis obliterans [110].
Some anticancer therapies, such as those targeting
erbB2 (an EGF receptor family member) with monoclo-
nal antibodies, might be considered for lung fibrosis
therapy to reduce mesenchymal cell survival and resolve
a fibrotic reaction. Finally, antifibrotic drugs tested in
the future could be more efficiently administered to tar-
get tissues via nanoparticle-mediated drug delivery,
although some caution should be used as some nano-
particles exacerbate airway fibrotic reactions in mouse
models of allergic asthma [111]. Mesenchymal survival
remains an important issue, and further research toward
controlling the survival of these cells should eventually
result in the development of effective treatments for
lung fibrotic diseases.
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